HMG

Based on FDA-approved labeling and pharmacokinetic studies of menotropins. E.g., 'Pharmacokinetics and Pharmacodynamics of Menotropin in Healthy Volunteers. Fertil Steril. 2007; 87(5):1093-1101.'

Dosing should ideally occur at a consistent time each day. For research protocols involving controlled ovarian stimulation, timing may be critical relative to other medications or procedures.

• hCG (Human Chorionic Gonadotropin)

  Often co-administered with HMG in both male and female fertility protocols to mimic the natural LH surge (in females for final oocyte maturation) or to stimulate Leydig cell function and testosterone production (in males for spermatogenesis).

  Synergistic

• GnRH Agonists/Antagonists

  Frequently used in conjunction with GnRH agonists or antagonists in ART protocols to prevent premature LH surges and allow for controlled ovarian stimulation. The specific protocol (e.g., 'long protocol,' 'short protocol,' 'antagonist protocol') dictates the timing and interaction.

  Compatible

• Clomiphene Citrate

  While sometimes used sequentially in fertility treatments, combining clomiphene with HMG requires careful monitoring due to potential for additive ovarian stimulation effects and increased risk of OHSS.

  Monitor Combination

• Corticosteroids

  No direct interaction with HMG. However, corticosteroids may be used in certain fertility protocols (e.g., immunological factors) and their systemic effects should be considered in overall subject management.

  Monitor Combination

• Other Hormonal Preparations (e.g., Estrogens, Androgens)

  The effects of HMG on reproductive hormones can be significantly altered by concomitant administration of other sex steroids. Careful consideration and monitoring are required to avoid counteracting or over-stimulating effects.

  Use Caution

1. 1Assemble all materials: vial of lyophilized HMG, bacteriostatic water for injection, sterile syringe(s) with needles, alcohol wipes.
2. 2Inspect the HMG vial for any damage or discoloration of the powder. Inspect the bacteriostatic water vial to ensure clarity and absence of particulate matter.
3. 3Clean the rubber stopper of both the HMG vial and the bacteriostatic water vial with alcohol wipes and allow to air dry.
4. 4Draw the desired amount of bacteriostatic water (e.g., 1mL per 75 IU/75 IU vial) into a sterile syringe.
5. 5Inject the bacteriostatic water slowly into the HMG vial, aiming the stream against the side of the vial to prevent foaming.
6. 6Gently swirl the vial to dissolve the powder completely. Do not shake vigorously, as this can denature the peptide. The solution should be clear and colorless.
7. 7Once dissolved, the solution is ready for administration. Withdraw the desired dose into a new sterile syringe.

Lyophilized powder should be reconstituted with bacteriostatic water for injection. The specific volume of diluent will depend on the desired concentration for administration and the total IU content per vial. Always follow manufacturer's instructions if available for specific products.

• In female research models, expect evidence of follicular growth and maturation, detectable via ultrasound and estradiol levels, within 5-12 days of initiation.
• In male research models with hypogonadotropic hypogonadism, expect gradual improvements in spermatogenesis, with sperm count increases potentially requiring several weeks to months of sustained administration.
• Some localized irritation, redness, or swelling at the injection site is common due to the injection process.
• Systemic effects, such as headache or abdominal discomfort, may be reported in some research subjects, particularly at higher doses.
• For human subjects, careful monitoring by a qualified research professional is essential to assess response and manage potential side effects.